Epidemiological situation of rickettsioses in EU/EFTA countries
This report characterises the different reporting systems for tick-borne rickettsioses in EU/EFTA countries and identifies and assesses the current epidemiological situation of these diseases. It is the first attempt to collect existing data on rickettsioses in EU/EFTA countries.
This report is the first effort to collect existing data on rickettsioses in EU/EFTA countries covering the period 2000–2010. It characterises the different reporting systems for tick-borne rickettsioses in EU/EFTA countries and identifies and assesses the current epidemiological situation of these diseases, in order to better understand the magnitude of tick-borne rickettsiosis in the region.
Rickettsioses are bacterial infectious diseases that occur in endemic areas across large regions of the world. They require the presence of competent reservoir hosts, vectors and the pathogen. Rickettsioses surveillance is currently implemented in 14 countries of the EU/EEA using different case definitions. Yet data from human cases should not be the only source of information to determine risk areas for infection.
As tick-borne pathogens are listed among emerging communicable disease globally, they are expected to constitute an increasing burden to societies due to increasing travel, increasing cohorts of immunocompromised persons, and ageing societies
Tick-borne rickesstioses epidemiology in EU and EFTA countries
Most of the cases of rickettsioses are reported from Italy, Portugal and Spain. In the most affected countries rickettsioses commonly occurred among males. The age distribution of cases was variable with cases among persons younger than 9 years and older than 60 years in Portugal and the older age group more affected in Spain.
Overview of the implementation of COVID-19 vaccination strategies and deployment plans in the EU/EEA
23 Sep 2021 - This report provides an updated overview of the progress of national COVID-19 vaccination strategies in EU/EEA countries, including updates on: vaccine uptake overall and by target group; current vaccination phases and priority groups, as well as any adjustments made to priority groups during the rollout; vaccination strategies and policies in place; and the use of vaccination certificates and challenges countries face with the rollout and good practices to mitigate these challenges.
HIV Continuum of care: Monitoring implementation of the Dublin Declaration on partnership to fight HIV/AIDS in Europe and Central Asia (2020 progress report)
16 Aug 2021 - In 2020, using data from countries able to provide at least two consecutive stages of the continuum, the overall performance of the European and Central Asian region against the global 90-90-90 targets is 82% of all PLHIV with HIV diagnosed, 67% of those diagnosed with HIV on treatment and 90% of those on treatment virally suppressed. More progress is needed to meet the substantive target of 73% of all PLHIV being virally suppressed, with performance for the overall region at 50% (based on the countries that submitted data for all four stages of the continuum).
Partial COVID-19 vaccination, vaccination following SARS-CoV-2 infection and heterologous vaccination schedule: summary of evidence
22 Jul 2021 - This document provides a review of evidence on three topics of interest (effectiveness of partial vaccination, immunogenicity and effectiveness of vaccination for previously infected individuals and safety and immunogenicity of heterologous schedules) to inform ongoing decision-making in relation to national vaccination policies and strategies in the European Union and European Economic Area (EU/EEA) countries.